The University of Chicago Header Logo

Connection

Randy Sweis to Maytansine

Back to Details
This is a "connection" page, showing publications Randy Sweis has written about Maytansine.
Randy Sweis
Connection Strength
0.208
Maytansine
  1. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
    View in: PubMed
    Score: 0.208
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.